How to cite item

Tumor mutational burden in non-small cell lung cancer—the pathologist’s point of view

   
@article{TLCR24601,
	author = {Frédérique Penault-Llorca and Nina Radosevic-Robin},
	title = {Tumor mutational burden in non-small cell lung cancer—the pathologist’s point of view},
	journal = {Translational Lung Cancer Research},
	volume = {7},
	number = {6},
	year = {2018},
	keywords = {},
	abstract = {In non-small cell lung cancer (NSCLC), the pathologist has contributed to the development of personalized medicine from the determination of the right histological type to EGFR and ALK/ROS1 molecular screening for targeted therapies. With the development of immunotherapies, pathologists intervene forefront with programmed death-ligand 1 (PD-L1) immunohistochemical testing, companion test for pembrolizumab monotherapy, first line and complementary test to the other programmed cell death-1 (PD-1) PD-L1 inhibitors. Recently, tumor mutational burden has emerged as a promising tool to evaluate sensitivity to immunotherapy (IO). The pathologist has a crucial role in the setting of tumor mutational burden (TMB) testing for the selection and the preparation of the sample for high throughput molecular analysis, and in the first steps of the next-generation sequencing (NGS) workflow.},
	issn = {2226-4477},	url = {https://tlcr.amegroups.org/article/view/24601}
}